- Conditions
- Leukemia, MDS, Myelofibrosis, Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
- Drug · Radiation · Other
- Lead sponsor
- Rafic Farah, MD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 3,576
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 25
- States / cities
- Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 18
- States / cities
- Duarte, California • San Francisco, California • Stanford, California + 13 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- ALLO-715, ALLO-647, Fludarabine, Cyclophosphamide, Nirogacestat
- Genetic · Biological · Drug
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Duarte, California • Palo Alto, California + 8 more
- Conditions
- Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Interventions
- Rosiglitazone and Bexarotene
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
- Interventions
- AMG 714, Placebo
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- San Diego, California • New York, New York
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Refractory
- Interventions
- HER2-specific T cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2037
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Interventions
- SHAPE
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM, Hospital Anxiety and Depression Scale, Duke-UNC Functional Social Support Questionnaire, Distress Thermometer, FACT-BMT, Psychosocial Assessments of Candidates for Transplantation
- Other · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 8
- States / cities
- Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
- Interventions
- Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation, T-Cell Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- CART-45 cells, CD45BE-HSPC
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2051
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Food Allergy, Eosinophilic Esophagitis
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Month to 65 Years
- Enrollment
- 5,300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2031
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Colorectal Cancer, Kidney Cancer
- Interventions
- lymphokine-activated killer cells, recombinant interferon alfa, sargramostim, fluorouracil
- Biological · Drug
- Lead sponsor
- St. Luke's Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Malignant Melanoma
- Interventions
- Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
- Combination Product
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Melanoma
- Interventions
- cyclophosphamide, Mature dendritic cell vaccine
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Bevacizumab, Interleukin-2
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Peripheral T-Cell Lymphoma
- Interventions
- Not listed
- Lead sponsor
- Associazione Angela Serra per la ricerca sul cancro
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Obesity and Obesity-related Medical Conditions
- Interventions
- Mounjaro, Sleeve Gastrectomy
- Drug · Procedure
- Lead sponsor
- Nicholas Skertich
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Nivolumab, cabiralizumab
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Columbus, Ohio • Madison, Wisconsin
- Conditions
- Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
- Interventions
- KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses, Cyclophosphamide 500 mg/m2; 2 doses, Fludarabine 30mg/m2 3 doses, Cyclophosphamide 500 mg/m2; 3 doses, Fludarabine 25mg/m2 3 days, Cyclophosphamide 250 mg/m2; 3 days, Tecartus, Abecma, Intravenous Suspension, Cyclophosphamide 900 mg/m2; 1 day, Breyanzi Injectable Product
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Sickle Cell Disease
- Interventions
- Bone Marrow Transplant (BMT), Hydroxyurea, Thiotepa, Fludarabine monophosphate, Cyclophosphamide, Rabbit Anti-thymocyte Globulin, Total Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infection
- Interventions
- Hydroxyurea
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland